Pharmacoeconomic review report : Sarilumab (Kevzara)

Pharmacoeconomic review report Sarilumab (Kevzara)

Sarilumab (Kevzara) for subcutaneous (SC) injection is a fully human immunoglobulin G1 monoclonal antibody that binds specifically to both soluble and membrane-bound interleukin-6 receptors inhibiting interleukin-6 mediated signalling. It is indicated for the treatment of adult patients with moderat...

Descripción completa

Detalles Bibliográficos
Autor principal: Canadian Agency for Drugs and Technologies in Health (author)
Autor Corporativo: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Ottawa (ON) : CADTH 2017.
Colección:Common drug review clinical review report.
Materias:
Arthritis > Treatment.
Cost effectiveness.
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820268006719
Tabla de Contenidos:
  • Abbreviations
  • Executive Summary
  • Background
  • Summary of the Economic Analysis Submitted by the Manufacturer
  • Key Limitations
  • Issues for Consideration
  • Results / Conclusions
  • Cost Comparison Table
  • APPENDIX 1. Reviewer Worksheets
  • References.

Ejemplares similares